Oct 18,2022

Ontada will present at 2022 Association for Value-Based Cancer Care Summit

Ontada's team will take part in "How Long is the Last Mile? Real-World Evidence’s Vast Potential and Challenges in Oncology (Oct. 20, 3:15 p.m.-4 p.m.)" and "Utilization of Pathways in Precision Medicine to Impact Patient Care (Oct. 21, 8 a.m.-9 a.m.)" during the 2022 Association for Value-Based Cancer Care Summit. The Summit, to be held Oct. 19-21, 2022, in New York City, is an invitational forum that provides invaluable access to more than 200 diverse experts representing every stakeholder of the cancer care ecosystem.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 20,2022 TOP STORY

FDA clears AI-enabled MR tech from Philips

Philips (NYSE:PHG) announced today that it received FDA 510(k) clearance for its AI-enabled MRCAT head and neck radiotherapy application. Amsterdam-based Philips designed its MRCAT head and neck application to allow for the use of MR as the sole or primary imaging modality for radiotherapy planning. It is used for the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis and prostate.

REGULATORY FDA

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 03,2022

OncoHost preparing launch of proteomics diagnostics platform for cancer, immunotherapy

OncoHost said on Monday that it is preparing to launch Prophet, a proteomics and artificial intelligence-based decision support diagnostics platform for advanced cancer patients undergoing immunotherapy.

PRODUCT

#platform

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 04,2022

Jasper Health and Scripps Research Partner to Embark on Oncology Research

Jasper Health and Scripps Research have entered a longstanding partnership with the goal of advancing the body of literature on improving the lives and outcomes of those affected by cancer. The partnership’s research will be focused on the role of biometrics data in cancer patients and then more broadly, the effects of digital and human-led cancer care navigation and support on quality of life and longitudinal patient outcomes.

COLLABORATION PARTNERSHIP

#r&d

#platform

View Analyst & Ambassador Comments
Go to original news
Oct 06,2022

It’s Not All about the Benjamins – Other Hurdles Presented by Research Participation, and why Payment won’t Resolve Them

COTA’s Chief Medical Officer, C.K. Wang recently spoke at the 2022 Office of Human Research Protections (OHRP) exploratory workshop, Beyond altruism – Exploring payment for research participation. Here is a summary of his comments prepared by the OHRP and the Department of Health and Human Services.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 06,2022

Massive Bio and Perthera.ai Partner to Empower Cancer Patients with Personalized Therapies and Accurate Trial Recommendations

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with biomarker-based therapy options. By combining the advanced computational methods and artificial intelligence capabilities of both companies, more physicians and patients will be able to confidently access the benefits of investigational precision oncology treatments from FDA-approved and novel therapies that are specific to patients’ unique molecular and genetic biomarkers. Perthera.ai combines multi-omic testing results (DNA, RNA, IHC and phosphoproteomics) to advise oncologists and their patients and simplify the decision-making process to increase the chance that the best therapy is used the first time.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Oct 25,2022 TOP STORY

COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation

COTA, Inc., an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management, a healthcare investment firm. Deerfield invests across the life science, medical device, diagnostic, digital health, and health service industries at every stage of evolution. In conjunction, COTA announced it has raised additional capital from existing investors. The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drug development in oncology.

FUNDING SERIES E
View Analyst & Ambassador Comments
Go to original news
Oct 27,2022 TOP STORY

Massive Bio Onboards Over 100,000 Cancer Patients to Find Their Clinical Trial, Powered by Artificial Intelligence

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, today announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022 – nine months sooner than expected.

CLINICAL STUDY

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Nov 02,2022

Accuray Reports Fiscal 2023 First Quarter Financial Results

Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2023 ended September 30, 2022. Some of the recent operational highlights are: data published in The Lancet Oncology indicate men with prostate cancer treated with the CyberKnife® System experienced lower incidence of certain bladder side effects; and the new, global commercial partnership of Accuray with GE Healthcare to expand access, advance Precision Radiation Therapy.

View Analyst & Ambassador Comments
Go to original news
Jan 04,2021

GAIA's Project NEVERMIND Becomes a Success Story

GAIA’s research project „Nevermind“ is published in the official „Success Story Yearbook 2020“ as one of nine EU funded projects related to digital technologies. The yearbook is released by The National Contact Point for European Research Funding on Information and Communication Technologies (NKS-IKT). In the project „Nevermind“ GAIA explored together with outstanding partners in Europe – such as the Karolinska Institut – how a digital health application can be integrated with smart-sensor technology to detect and treat depression among patients with diseases such as heart disease, cancer, or kidney failure. The research was based on GAIA’s app deprexis® and a smart shirt.

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY